Decoding PharmEasy’s latest down round logic

The proposed rights issue, at a 90% valuation cut, makes one thing clear: it’s the investors who are calling the shots here.

7 July, 20234 min
0
Google Preferred Source Badge
Share
Getting your Trinity Audio player ready...
Decoding PharmEasy’s latest down round logic

You may also like

Business
Story image

IPO is imperative but no panacea for Manipal Hospitals

A public listing will help clean up the hospital chain’s balance sheet after the costly Sahyadri acquisition. But depressed metrics, integration risks and lofty valuations make this far from a clean turnaround story.

Business
Story image

Growth alone isn’t enough, Waaree needs to do more

The solar module maker’s investors want proof of its durability in the face of a leadership change and a costly push into energy storage.

Business
Story image

The weight-loss wave that’s changing India—one sector at a time

Mounjaro’s blockbuster debut has already sparked a seismic shift across Indian healthcare, diagnostics and pharma. A marked change in consumer behaviour looks imminent.